Gu
Gustave Roussy
NPVillejuif FRFounded 19263,500 employees
Private CapacadPrivateOncology
Platform: EU Cancer Ctr
Market Cap
N/A
All Drugs
6
Clinical Trials
6
Failed / Terminated
0
FDA Approved
1
Drug Pipeline (6 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| GUS-IIT-540 | GUS-IIT-540 | Phase 1/2 | 1 | TYK2 | Dravet | ||
| GUS-IIT-951 | GUS-IIT-951 | Approved | 1 | USP1 | LGS | ||
| GUS-IIT-973 | GUS-IIT-973 | Phase 2 | 1 | GPRC5D | RSV | ||
| GUS-IIT-564 | GUS-IIT-564 | Phase 3 | 1 | PD-1 | PSP | ||
| GUS-IIT-662 | GUS-IIT-662 | Preclinical | 1 | JAK2 | PTSD | ||
| GUS-IIT-176 | GUS-IIT-176 | Phase 2/3 | 1 | TROP-2 | FL |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)